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INTRODUCTION
Respiratory syncytial virus (RSV) is the major viral cause
of respiratory illness and is associated with life-threatening
complications in young infants between 8 and 30 weeks of
age (1, 2). RSV infection causes acute inflammation, edema,
and necrosis of epithelial cells of the small airways, and is
associated with increased mucus production and broncho-
spasm. Overall, mechanical ventilation with intensive care
is needed in 1-2% of children with RSV infections (3-5),
and worldwide RSV infection accounts for 600,000 deaths
per year (3, 6). 
Compared to full-term infants, premature infants (less than
35 weeks gestation) are at higher risk for severe lung disease
and respiratory failure due to their immature lungs, unfavor-
able pulmonary compliance, high airway resistance, and fri-
able chest wall. Therefore, RSV infection is associated with
a higher morbidity and mortality in premature infants (7, 8). 
Various therapeutic interventions including bronchodila-
tors, corticosteroids, ribavirin, chest physiotherapy, and oxy-
gen have been used for treatment; however, no specific ther-
apeutic method has been proven effective against RSV (4).
Recently, prevention of RSV infection has focused on passive
immunization with palivizumab prophylaxis.
Palivizumab, a humanized monoclonal immunoglobulin
G preparation against the F glycoprotein of RSV, was appr-
oved for use in the USA in 1998 and it was approved in Eu-
rope in 1999. In a placebo-controlled Impact-RSV trial in
the USA, intramuscular palivizumab prophylaxis was shown
to be safe and reduced RSV-related hospitalization in prema-
ture infants by 55% (9). 
In Korea, since 2005, palivizumab prophylaxis has been
used in premature children with chronic lung disease (CLD)
born at ≤35 weeks of gestation, in children <2 yr of age
that also received medical therapy (supplemental oxygen,
bronchodilator, diuretics, or corticosteroid therapy) within
six months prior to the RSV season. However, no data has
been published on the efficacy of palivizumab and patient
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Outcomes of Palivizumab Prophylaxis for Respiratory Syncytial Virus
Infection in Preterm Children with Bronchopulmonary Dysplasia at a
Single Hospital in Korea from 2005 to 2009
This study was performed to evaluate the utilization and outcomes of palivizumab
in high risk children born prematurely with chronic lung disease (CLD). A retrospec-
tive review of 128 patients was conducted from September 2004 to March 2009 at
the Ajou University Hospital. All patients were diagnosed with CLD, were born at
≤35 weeks of gestation, were <2 yr old at the onset of respiratory syncytial virus
(RSV) season, and had received medical therapy within six months prior to the
RSV season. Fifty-three patients did not receive palivizumab prophylaxis and 75
patients received at least one dose of palivizumab. There were no statistically sig-
nificant differences between the patients with and without palivizumab prophylaxis
with regard to demographic characteristics and risk factors for RSV infection. There
were no systemic adverse responses. Compliance with the course of prophylaxis
was 92.2%. Hospitalization associated with RSV occurred in 12 cases (22.6%) in
the group without prophylaxis and in three cases (4.0%) with prophylaxis. Palivizum-
ab prophylaxis significantly reduced the frequency of RSV-related hospitalization
in preterm children with CLD. This is the first retrospective review of palivizumab
prophylaxis in Korea. Palivizumab is effective and well tolerated in high risk prema-
turely born children.
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We retrospectively reviewed the clinical outcomes of pre-
mature children with CLD that received one or more doses
of palivizumab during the 2005 to 2009 RSV seasons and
the children that did not receive palivizumab during the
2004 to 2009 RSV seasons in Korea. The demographic, clin-
ical characteristics, respiratory illness, and RSV hospitaliza-
tions were compared between the two groups. 
The goals of the present study were to determine the safe-
ty and efficacy of palivizumab prophylaxis for reducing RSV
related illness among the high risk premature children with
CLD, and to provide information for the utilization and com-
pliance of palivizumab prophylaxis. 
MATERIALS AND METHODS
Patients
We retrospectively reviewed the clinical data of preterm
children between September 2004 and March 2009 at the
Ajou University Hospital. During the periods, 135 patients
needed for oxygen >21% for at least 28 days and had the
clinical diagnosis of CLD (or bronchopulmonary dysplasia).
The inclusion criteria specified that children were born at
≤35 weeks of gestation, were <2 yr of age at the onset of
the RSV season, and had received medical therapy (supple-
mental oxygen, bronchodilator, diuretics, or corticosteroid
therapy) within six months prior to the RSV season. Chil-
dren were excluded if they had any of the following: known
renal impairment, hepatic dysfunction, immunodeficiency,
neuromuscular impairment, chromosomal anomalies, con-
genital metabolic diseases, major congenital anomalies, or
congenital heart disease with cyanosis or heart failure except
for those with a patent ductus arteriosus or a septal defect
that was uncomplicated and hemodynamically insignificant. 
Among the 135 patients with CLD, seven patients were
excluded. They had the clinical diagnosis of tetralogy of Fal-
lot (n=1), tracheoesophageal fistula (n=2), congenital dia-
phragmatic hernia (n=1), 18 trisomy (n=1), congenital hydro-
cephalus (n=1) and Goltz syndrome (n=1). We enrolled 128
patients with CLD and reviewed their clinical course. Fifty
three patients did not receive palivizumab prophylaxis and
75 received at least one dose of palivizumab. 
Personal information was collected including demograph-
ics (birth weight, gestational age), neonatal course as well as
medical and family history. Injection information included
the date, dose, frequency, intervals and the response to the
injections over seven days after the injection. Data, specific
to hospitalization for respiratory illness, included the type
of respiratory infection, hospital stay, isolated microorgan-
isms or viruses, treatment, and dates. The study protocol
and procedures were reviewed and approved by the Institu-
tional Review Board of Ajou University Hospital. 
Palivizumab prophylaxis
Palivizumab (Synagis
�, Boehringer Ingelheim Pharma,
Biberach an der Riss, Germany) prophylaxis was provided
from September to March. Patients received palivizumab
(15 mg/kg) by intramuscular injection every 30 days. Palivi-
zumab was supplied as a lyophilized powder in vials that were
reconstituted with sterile water for injection and dispensed
as a unit dose in a syringe. The final concentration of palivi-
zumab was 100 mg/mL. 
Clinical diagnosis, definition and indications for 
hospitalization
The severity of CLD (or bronchopulmonary dysplasia) was
classified by the “new” bronchopulmonary dysplasia (BPD)
definition criteria (10). Patients hospitalized for respiratory
illness were classified into one of four clinical syndromes,
according to Denny and Clyde (11). 
RSV hospitalization was defined as any hospitalization
with a duration of 24 hr or longer in a patient with positive
RSV testing. The decision to admit to the hospital was based
on the guidelines of the Denver Children’s Hospital (Denver,
CO, USA) (12). Patients were admitted when they had a poor
response to oral medication and/or inhalation therapy, poor
oral feeding, apnea, hypoxia, signs of dehydration, and/or
signs of sepsis. 
Compliance with the injection regimen was determined
by comparing the actual number of injections received with
the expected number of doses, based on the month the first
injection was given. 
Virological methods
Nasopharyngeal aspirates were collected on hospital admis-
sion by inserting a 5 Fr nasogastric tube into the nasophar-
ynx with negative pressure suction. The aspirates were col-
lected into viral transport medium and delivered to the lab-
oratory. RSV was detected by either the immunofluorescence
rapid antigen test with the Respiratory Panel Viral Screen-
ing & Identification Kit
� (Chemicon, Temecula, CA, USA)
or RT-PCR. Virological tests were performed by the clinical
laboratory at the Seoul Medical Science Institute. 
Statistical analysis
The characteristics of the patients with and without pro-
phylaxis were compared with the Student’s t-test and Fish-
er’s exact test focusing on differences in demographic char-
acteristics, risk factors for RSV infection and RSV associated
hospitalization. The severity of BPD in these patients was
compared using Pearson chi-square tests. The data were en-
tered into a Microsoft Excel database and SPSS 11.0 was used
for the data analysis. 
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Patient characteristics
The characteristics of all patients are summarized in Table
1. All patients received oxygen therapy for more than 28 days
after birth. A total of 53 patients did not receive palivizum-
ab prophylaxis. Twenty one patients were diagnosed during
the 2004 to 2005 RSV season prior to the approval of pali-
vizumab prophylaxis, and 32 patients did not receive palivi-
zumab because their parents declined the injection due to
financial problems. Seasonal RSV prophylaxis injections were
given to 75 children between September 2005 and March
2009. 
There were no significant differences in the neonatal demo-
graphics including gestational age, birth weight, gender, and
type of delivery. The follow-up duration and initial duration
of the hospital stay showed no statistically significant differ-
ences. The severity of BPD and co-morbidities included mul-
tiple births, congenital heart disease, and patent ductus arte-
riosus; there were no statistically significant differences among
these factors (Table 1). 
Characteristics and response to palivizumab injections
Seventy one patients received one season of prophylaxis; a
second-season of prophylaxis was given to one patient with
moderate BPD and three patients with severe BPD. Palivi-
zumab prophylaxis increased during the 2008 to 2009 RSV
season (Table 1). Palivizumab injection was started at the
neonatology intensive care unit in 63 patients. A total of 284
injection doses were provided. The mean±SD of received
injections was 3.4±1.6 (range 1-6). A total of six doses were
injected in four patients. All of the expected injections were
given to 62 patients. Compliance (Actual No. of injections/
No. of recommended injections×100) was 92.2%. None of
the patients dropped out; however, the last injection dose
was not received in 13 patients. The mean interval between
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Significance was tested using *Student’s t-test, 
� Fisher’s exact test and 
� Pearson chi-square tests.
Values are expressed as numbers of patients or mean±SD.
RSV, respiratory syncytial virus; BPD, bronchopulmonary dysplasia.
Parameters
Non-prophylaxis group
(n=53)
Palivizumab-prophylaxis group
(n=75)
P value
Enrollment period of RSV season 9/1/2004-3/31/2009 9/1/2005-3/31/2009
9/1/2004-3/31/2005 21
9/1/2005-3/31/2006 12 14
9/1/2006-3/31/2007 11 13
9/1/2007-3/31/2008 6 19
9/1/2008-3/31/2009 3 33
Male:Female 33:20 39:36 0.561
�
Gestational age  29.4±2.2 28.1±1.7 0.130*
<28 weeks  14 35
28-31 weeks  31 38
32-35 weeks  8 2
Birth weight  1,182±204 1,072±223 0.382*
<1,000 g  10 28
1,000-1,500 g 37 43
>1,500 g 6 4
Type of delivery 
Vaginal delivery:Cesarean section 12:41 24:51 0.781
�
Age at start of palivizumab injection (months) - 3.5±3.0
Follow up duration (months) 18.3±7.8 16.9±10.9 0.090*
Initial hospital stay (days) 72.3±28.2 76.0±39.7 0.507*
BPD
Mild:Moderate:Severe 18:17:18 27:28:20 0.093
�
Risk factors other than BPD
Multiple birth 5 10 0.090
�
Congenital heart disease
Patent ductus arteriosus 8 13 0.253
�
Atrial septal defect 0 1 0.051
�
Cystic fibrosis 0 0
Siblings of childcare attendance 23 35 0.257
�
Smoke exposure 13 24 0.609
�
Table 1. Comparison of demographics and clinical characteristics including risk factors for RSV infection between patients without pro-
phylaxis and with palivizumab-prophylaxisinjections was 31.3 days; all doses were given within 35 days
after previous injection. 
There were no systemic, respiratory or gastrointestinal sym-
ptoms noted after the injections. Erythema and swelling at
the injection site was noted in three patients, and subsided
within three days (Table 2). 
Respiratory hospitalization
Overall, respiratory hospitalizations occurred in 23 patients
that did not receive prophylaxis and in 32 patients that recei-
ved palivizumab prophylaxis. The total number of respira-
tory hospitalizations, characteristics of lower respiratory tract
infections (LRTI), and the length of hospital stay showed no
statistically significant differences between patients with or
without prophylaxis. Of 55 hospitalized patients, 49 patients
were tested for laboratory tests for RSV. The rate of LRTI
hospitalizations associated with RSV was 22.6% (12/53) in
cases without prophylaxis and 4.0% (3/75) in cases with pro-
phylaxis. Monthly prophylaxis with palivizumab significant-
ly reduced the RSV associated hospitalization. Intubation
and intensive care were needed in four patients with RSV,
in two patients with a metapneumovirus infection, and in
one patient with parainfluenza infection. One of the patients
without prophylaxis, with RSV, died while receiving inten-
sive care treatment with mechanical ventilation in January
2005. The length of the RSV hospital stay was not signifi-
cantly different between the two groups (Table 3). Prior to
the hospitalization for RSV, 14 patients were at home and
one patient who received prophylaxis was in a rehabilitation
facility. RSV hospitalizations occurred throughout the RSV
season and in April (Table 4). Of the patients who received
RSV prophylaxis, RSV was detected 31 days after previous
prophylaxis in two patients, and 32 days after previous pro-
phylaxis in one patient, respectively. 
DISCUSSION
A long term surveillance study in Korea showed that RSV
was the most common cause of LRTI among young children
(13-16); and readmissions to the hospital for RSV infection
has been reported to be 22.2% in premature infants (17). 
Outbreaks of RSV occur annually worldwide. In the USA,
outbreaks of RSV typically begin in November or Decem-
ber, peak in January or February, and end in March or April
(18). A pilot study to establish a nationwide surveillance
system was started in 2005 by the Korean Centers for Dis-
ease Control and Prevention (KCDC). The KCDC defines
the RSV season from October to March in Korea; however,
the season varied considerably year by year (13-16). 
Occurrence of RSV disease is inevitable especially during
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Responses No. of cases
Anaphylaxis 0
Fever 0
Erythema 2
Swelling 1
Rash 0
AST elevation 0
ALT elevation 0
Cough 0
Wheezing 0
Vomiting 0
Diarrhea 0
Table 2. Adverse responses following palivizumab injections
AST, aspartate aminotransferase; ALT, alanine aminotransferase.
Parameters
Non-pro-
phylaxis
group
(n=53)
Palivizumab-
prophylaxis
group
(n=75)
P
Total respiratory hospitalization   23 32 0.818
�
including RSV
Lower respiratory tract infection  23 28 0.765
�
Croup:Bronchiolitis:Pneumonia 1:12:10 7:12:9
Length of stay in respiratory  11.3±7.2 8.1±5.6 0.090*
hospitalization (days)
RSV test in respiratory hospitalized  17/23 32/32
patients 
Confirmed RSV hospitalization  12 (22.6) 3 (4.0)  <0.001
�
RSV length of stay (days) 12.7±5.4 13.7±6.5 0.209*
Intensive care with intubation  4 (3
� ) 3 (1
� ) 0.871
�
Death due to RSV  1
� 0 0.621
�
Table 3. Comparison of respiratory hospitalizations between pa-
tients without prophylaxis and with palivizumab-prophylaxis
Significance was tested using *Student’s t-test, 
� Fisher’s exact test, 
� Nu-
mber of RSV confirmed patients.
Values are expressed as numbers (%) of patients or mean±SD. 
RSV, respiratory syncytial virus.
Timing by
month
Number of patients
Non-prophylaxis group
(n=53)
Palivizumab-prophylaxis
group (n=75)
January 4 (1) 4 (1)
February 3 (3) 6
March 3 (1) 2
April 2 5 (1)
May 2 1
June 0 3
July 1 4
August 1 1
September 5 (1) 1
October 3 (1) 7
November 1 (2) 6 (1)
December 6 (3) 5
Table 4. Respiratory hospitalization including RSV infection for
all patients by month
Number in parenthesis is number of RSV confirmed patients.
RSV, respiratory syncytial virus.seasons. Therefore, prevention is essential for decreasing the
morbidity and mortality associated with the disease. After
US FDA approval in 1998, palivizumab prophylaxis has
been used in many countries (19-23). The data from the Pali-
vizumab Outcomes Registry in the USA showed that the
incidence of RSV hospitalization was decreased with palivi-
zumab prophylaxis (21) and the majority of RSV hospital-
izations occurred between the first and second dose injec-
tions (22). 
The American Academy of Pediatrics has revised its evi-
dence-based guidelines for RSV immunoprophylaxis with
palivizumab. The 2003 guidelines recommended palivizum-
ab prophylaxis in certain preterm infants without co-mor-
bidities: 1) children born at 28 weeks gestation or earlier that
are 12 months of age or less at the start of RSV season, 2)
children born at 29 to 32 weeks gestation that are 6 months
of age or less at the start of RSV season, and 3) children born
at 32 to 35 weeks gestation that are 6 months of age or less
at the start of RSV season and have at least two risk factors.
The risk factors include congenital abnormalities of the air-
ways, severe neuromuscular disease, child-care attendance,
exposure to environmental air pollutants, and school-aged
siblings (24, 25). 
Since 2005, we have provided palivizumab prophylaxis to
certain children born prematurely with CLD. According to
the National Health Insurance Corporation of Korea, palivi-
zumab prophylaxis is only indicated in children with CLD
that have received medical therapy (supplemental oxygen,
bronchodilator therapy, diuretics, or corticosteroid therapy)
within 6 months prior to the RSV season, and are 2 yr of age
or younger at the start of RSV season.
This is the first retrospective review of palivizumab pro-
phylaxis, performed from the first year of prophylaxis to the
most current RSV season in Korea. In this study, palivizum-
ab prophylaxis was provided to children born prematurely
with CLD. A total of 75 patients received palivizumab injec-
tions. However, palivizumab prophylaxis was declined in
32 patients by their parents from 2005 to 2009. Palivizum-
ab prophylaxis was given to more infants from 2007 to 2009,
during the RSV seasons (Table 1). The economic support
from the National Health Insurance Corporation of Korea
for prophylaxis has increased starting in 2007. Reducing
the economic burden of prophylaxis was helpful for parent
agreement. Interruption of prophylaxis (13/75) was most
commonly related to economic burden. 
Although this study was not a randomized, double-blind,
placebo-controlled trial, the demographic characteristics and
co-morbidities were not different significantly between pati-
ents with and without prophylaxis (Table 1). Palivizumab
prophylaxis showed an 82% reduction of RSV-associated
hospitalization compared to the patients without prophy-
laxis. In the present study, the overall frequency of RSV hos-
pitalization among premature children with CLD in the pati-
ents that received palivizumab prophylaxis (4.0%). The rate
was lower than those reported, in the Impact-RSV clinical
trial (7.9%) (9), in the Outcome Registry of USA in 2000-
2001 (5.8%) (22), in Canada in 1999-2000 (6.0%) (19) and
in a cohort study in Europe during 2000-2002 (11.35%) (21).
RSV testing was not routinely performed in the outpa-
tient setting; and this is a limitation of this study. The data
reported here might therefore underestimate the true inci-
dence of RSV-related infection. During the follow-up, how-
ever, the total frequency of respiratory hospitalizations and
requirement for mechanical ventilation were not significant-
ly different according to palivizumab prophylaxis (Table 3);
it is not clear whether palivizumab prophylaxis itself allevi-
ates the severity of the respiratory illness. 
In all of three RSV hospitalized patients who received pro-
phylaxis, RSV was confirmed just prior to the date of sched-
uled injections. Because these patients had weight gains of
750 to 1,000 g over one month, we assumed that relative
activity of the specific IgG against RSV antigen may not be
sufficient in these patients. However, we could not confirm
this. Also, we could not examine thoroughly the risk factors
associated with the failure of palivizumab prophylaxis in these
cases. 
RSV hospitalization in one patient occurred in April after
KCDC definitioning season. A children born prematurely
with CLD are susceptible to respiratory infections through-
out the year (Table 4). Therefore, for the efficacy of prophy-
laxis, further study is required including consideration of
the variation of RSV outbreaks in Korea.
In conclusion, this is the first study to report on the uti-
lization and outcomes of palivizumab prophylaxis in Korea.
Palivizumab prophylaxis was effective, well-tolerated, and
compliance was high in the children born prematurely with
CLD that were at high risk for developing severe RSV in-
fection. Palivizumab prophylaxis reduced RSV hospitaliza-
tion significantly (22.6% vs. 4.0% in without and with pali-
vizumab prophylaxis, retrospectively). This result is a favor-
able outcome when compared to the trial conducted in the
USA, data from Outcome Registries, and other prospective
studies in different countries. This information can be used
to determine the efficacy of palivizumab prophylaxis in chil-
dren at high risk of RSV infection.
REFERENCES
1. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl
Med 2001; 344: 1917-28.
2. Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR. Rates
of hospitalization for respiratory syncytial virus infection among chil-
dren in medicaid. J Pediatr 2000; 137: 865-70.
3. Holman RC, Shay DK, Curns AT, Lingappa JR, Anderson LJ. Risk
factors for bronchiolitis-associated deaths among infants in the Unit-
ed States. Pediatr Infect Dis J 2003; 22: 483-90.
4. American Academy of Pediatrics Subcommittee on Diagnosis and
Outcomes of Palivizumab Prophylaxis in Preterm Children with Bronchopulmonary Dysplasia 255Management of Bronchiolitis. Diagnosis and management of bron-
chiolitis. Pediatrics 2006; 118: 1774-93.
5. Loughlin GM, Moscona A. The cell biology of acute childhood res-
piratory disease: therapeutic implications. Pediatr Clin North Am
2006; 53: 929-59.
6. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Ander-
son LJ, Fukuda K. Mortality associated with influenza and respira-
tory syncytial virus in the United States. JAMA 2003; 289: 179-86.
7. Thorburn K. Pre-existing disease is associated with a significantly
higher risk of death in severe respiratory syncytial virus infection.
Arch Dis Child 2009; 94: 99-103.
8. Sampalis JS. Morbidity and mortality after RSV-associated hospital-
izations among premature Canadian infants. J Pediatr 2003; 143 (5
Suppl): S150-6.
9. The Impact-RSV Study Group. Palivizumab, a humanized respira-
tory syncytial virus monoclonal antibody, reduces hospitalization
from respiratory syncytial virus infection in high-risk infants. Pedi-
atrics 1998; 102: 531-7.
10. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir
Crit Care Med 2001; 163: 1723-9.
11. Denny FW, Clyde WA Jr. Acute lower respiratory tract infections
in nonhospitalized children. J Pediatr 1986; 108: 635-46.
12. Simoes EA. Respiratory syncytial virus infection. Lancet 1999; 354:
847-52.
13. Kim YK, Nyambat B, Hong YS, Lee CG, Lee JW, Kilgore PE. Bur-
den of viral respiratory disease hospitalizations among children in
a community of Seoul, Republic of Korea, 1995-2005. Scand J Infect
Dis 2008; 40: 946-53.
14. Ahn KM, Chung SH, Chung EH, Koh YJ, Nam SY, Kim JH, Son
JA, Park JY, Lee NY, Lee SI. Clinical characteristics of acute viral
lower respiratory tract infections in hospitalized children in Seoul,
1996-1998. J Korean Med Sci 1999; 14: 405-11.
15. Kim MR, Lee HR, Lee GM. Epidemiology of acute viral respirato-
ry tract infections in Korean children. J Infect 2000; 41: 152-8.
16. Choi EH, Lee HJ, Kim SJ, Eun BW, Kim NH, Lee JA, Lee JH, Song
EK, Kim SH, Park JY, Sung JY. The association of newly identified
respiratory viruses with lower respiratory tract infections in Korean
children, 2000-2005. Clin Infect Dis 2006; 43: 585-92.
17. Lee EA, Jeong JH, Yu ST, Lee CW, Yoon HS, Park DS, Oh YK.
Incidence and risk factors of rehospitalization with respiratory syn-
cytial virus infection in premature infants. Korean J Pediatr 2004;
47: 510-4.
18. Centers for Disease Control and Prevention (CDC). Brief report: res-
piratory syncytial virus activity-United States, 2005-2006. MMWR
Morb Mortal Wkly Rep 2006; 55: 1277-9.
19. Oh PI, Lanctj^t KL, Yoon A, Lee DS, Paes BA, Simmons BS, Pari-
son D, Manzi P. Palivizumab prophylaxis for respiratory syncytial
virus in Canada: utilization and outcomes. Pediatr Infect Dis J 2002;
21: 512-8.
20. Sorrentino M, Powers T. Effectiveness of palivizumab: evaluation
of outcomes from the 1998 to 1999 respiratory syncytial virus sea-
son. The Palivizumab Outcomes Study Group. Pediatr Infect Dis J
2000; 19: 1068-71. 
21. Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M,
Boron M; Palivizumab Outcomes Registry Group. Prevention of
hospitalization due to respiratory syncytial virus: results from the
Palivizumab Outcomes Registry. J Perinatol 2008; 28: 511-7.
22. Palivizumab Outcomes Registry Study Group. Palivizumab prophy-
laxis of respiratory syncytial virus disease in 2000-2001: results from
The Palivizumab Outcomes Registry. Pediatr Pulmonol 2003; 35:
484-9.
23. Saji BT. Indications, efficacy and Safety of Anti-RS Virus Monoclon-
al Antibody Palivizumab (Synagis) for Pediatric Patients With Con-
genital Heart Diseases. J Korean Pediatr Cardiol Soc 2007; 11: 149-
50.
24. American Academy of Pediatrics Committee on Infectious Diseases
and Committee on Fetus and Newborn. Revised indications for the
use of palivizumab and respiratory syncytial virus immune globulin
intravenous for the prevention of respiratory syncytial virus infec-
tions. Pediatrics 2003; 112: 1442-6.
25. American Academy of Pediatrics. Red-book: 2006 report of the com-
mittee on infectious disease. 27th ed. Elk Grove, IL: American Acade-
my of Pediatrics; 2006.
256 S.G. Chang, M.S. Park, and J.E. Yu